Department of Pharmacy, Banner University Medical Center, Tucson, AZ 85719, USA.
Department of Pharmacy, University of Arizona Cancer Center, Tucson, AZ 85719, USA.
Future Oncol. 2017 Oct;13(25):2285-2295. doi: 10.2217/fon-2017-0374. Epub 2017 Sep 5.
Biosimilar medicines offer significant cost-savings potential over their reference products, which can be re-allocated to provide access to other cancer treatments on a budget-neutral basis.
Simulation study using cost data for the USA under consideration of several prophylaxis patterns.
Potential savings from conversion from reference filgrastim to biosimilar filgrastim-sndz are significant. These savings expand budget-neutral access to novel immunotherapies (obinutuzumab; pembrolizumab) or supportive care (filgrastim-sndz).
The combination of biosimilar savings and expanded access increases the value of cancer care as the same supportive care is provided at lower cost, additional cancer care is enabled at no additional cost, and more patients will have access to cancer care.
生物类似药相对于其参照产品具有显著的成本节约潜力，这些节约的成本可以重新分配，在不增加预算的情况下为其他癌症治疗提供可及性。
使用美国的成本数据进行模拟研究，考虑了几种预防方案。
将参照用非格司亭转换为生物类似药非格司亭-sndz 可节省大量成本。这些节省可扩大对新型免疫疗法（奥滨尤妥珠单抗；帕博利珠单抗）或支持性护理（非格司亭-sndz）的预算中性可及性。
生物类似药节省和扩大可及性的结合增加了癌症护理的价值，因为以更低的成本提供相同的支持性护理，无需额外成本即可获得更多的癌症治疗，更多的患者将获得癌症护理。
